Targeted migration of mesenchymal stem cells modified with CXCR4 gene to infarcted myocardium improves cardiac performance - PubMed (original) (raw)
doi: 10.1038/sj.mt.6300374. Epub 2008 Feb 5.
Affiliations
- PMID: 18253156
- DOI: 10.1038/sj.mt.6300374
Free article
Targeted migration of mesenchymal stem cells modified with CXCR4 gene to infarcted myocardium improves cardiac performance
Zhaokang Cheng et al. Mol Ther. 2008 Mar.
Free article
Abstract
With the goal of devising a non-invasive cell therapy for cardiac repair that may be well tolerated by patients with myocardial infarction (MI), this study evaluated the efficacy of intravenous infusion of genetically modified mesenchymal stem cells (MSCs) overexpressing CXC chemokine receptor 4 (CXCR4). CXCR4 is the cognate receptor for stromal-derived factor-1 (SDF-1), a chemokine required for homing of progenitor cells to ischemic tissues. In this study, retrovirally transduced MSCs constitutively expressing CXCR4 (CXCR4-MSCs) were delivered intravenously 24 hours after coronary occlusion/reperfusion in rats. When compared with untransduced MSCs, CXCR4-MSCs homed in toward the infarct region of the myocardium in greater numbers. In the CXCR4-MSC-treated animals, echocardiographic imaging 30 days after MI showed a decrease in anterior wall thinning and good preservation of left ventricular (LV) chamber dimensions, whereas the animals treated with saline or unmodified MSCs showed significant remodeling. Histochemical analysis showed a decrease in collagen I/III ratio in the infarcted wall of CXCR4-MSC-treated animals, thereby suggesting improved chamber compliance. Assessment revealed post-MI recovery of LV function in the CXCR4-MSC-treated animals, whereas LV function remained depressed in the saline and MSC-treated animals. In summary, intravenous delivery of genetically modified MSCs expressing CXCR4 may be a useful, non-invasive, and safe therapeutic strategy for post-infarction myocardial repair.
Similar articles
- Thioredoxin-1 (Trx1) engineered mesenchymal stem cell therapy increased pro-angiogenic factors, reduced fibrosis and improved heart function in the infarcted rat myocardium.
Suresh SC, Selvaraju V, Thirunavukkarasu M, Goldman JW, Husain A, Alexander Palesty J, Sanchez JA, McFadden DW, Maulik N. Suresh SC, et al. Int J Cardiol. 2015 Dec 15;201:517-28. doi: 10.1016/j.ijcard.2015.08.117. Epub 2015 Aug 15. Int J Cardiol. 2015. PMID: 26322599 - Mobilization of mesenchymal stem cells by granulocyte colony-stimulating factor in rats with acute myocardial infarction.
Cheng Z, Liu X, Ou L, Zhou X, Liu Y, Jia X, Zhang J, Li Y, Kong D. Cheng Z, et al. Cardiovasc Drugs Ther. 2008 Oct;22(5):363-71. doi: 10.1007/s10557-008-6110-2. Epub 2008 May 7. Cardiovasc Drugs Ther. 2008. PMID: 18461431 - Preconditioning enhances cell survival and differentiation of stem cells during transplantation in infarcted myocardium.
Pasha Z, Wang Y, Sheikh R, Zhang D, Zhao T, Ashraf M. Pasha Z, et al. Cardiovasc Res. 2008 Jan;77(1):134-42. doi: 10.1093/cvr/cvm025. Epub 2007 Sep 22. Cardiovasc Res. 2008. PMID: 18006467 - Extracardiac-Lodged Mesenchymal Stromal Cells Propel an Inflammatory Response Against Myocardial Infarction via Paracrine Effects.
Peng Y, Pan W, Ou Y, Xu W, Kaelber S, Borlongan CV, Sun M, Yu G. Peng Y, et al. Cell Transplant. 2016;25(5):929-35. doi: 10.3727/096368915X689758. Epub 2015 Oct 22. Cell Transplant. 2016. PMID: 26498018 Review. - Mesenchymal stem cell therapy: A promising cell-based therapy for treatment of myocardial infarction.
Shafei AE, Ali MA, Ghanem HG, Shehata AI, Abdelgawad AA, Handal HR, Talaat KA, Ashaal AE, El-Shal AS. Shafei AE, et al. J Gene Med. 2017 Dec;19(12). doi: 10.1002/jgm.2995. Epub 2017 Dec 8. J Gene Med. 2017. PMID: 29044850 Review.
Cited by
- Genetic Engineering as a Strategy to Improve the Therapeutic Efficacy of Mesenchymal Stem/Stromal Cells in Regenerative Medicine.
Damasceno PKF, de Santana TA, Santos GC, Orge ID, Silva DN, Albuquerque JF, Golinelli G, Grisendi G, Pinelli M, Ribeiro Dos Santos R, Dominici M, Soares MBP. Damasceno PKF, et al. Front Cell Dev Biol. 2020 Aug 21;8:737. doi: 10.3389/fcell.2020.00737. eCollection 2020. Front Cell Dev Biol. 2020. PMID: 32974331 Free PMC article. Review. - Harnessing the mesenchymal stem cell secretome for the treatment of cardiovascular disease.
Ranganath SH, Levy O, Inamdar MS, Karp JM. Ranganath SH, et al. Cell Stem Cell. 2012 Mar 2;10(3):244-58. doi: 10.1016/j.stem.2012.02.005. Cell Stem Cell. 2012. PMID: 22385653 Free PMC article. Review. - Empowering adult stem cells for myocardial regeneration.
Mohsin S, Siddiqi S, Collins B, Sussman MA. Mohsin S, et al. Circ Res. 2011 Dec 9;109(12):1415-28. doi: 10.1161/CIRCRESAHA.111.243071. Circ Res. 2011. PMID: 22158649 Free PMC article. Review. - Transplanted bone marrow-derived circulating PDGFRα+ cells restore type VII collagen in recessive dystrophic epidermolysis bullosa mouse skin graft.
Iinuma S, Aikawa E, Tamai K, Fujita R, Kikuchi Y, Chino T, Kikuta J, McGrath JA, Uitto J, Ishii M, Iizuka H, Kaneda Y. Iinuma S, et al. J Immunol. 2015 Feb 15;194(4):1996-2003. doi: 10.4049/jimmunol.1400914. Epub 2015 Jan 19. J Immunol. 2015. PMID: 25601922 Free PMC article. - Progenitor/stem cell transplantation for repair of myocardial infarction: Hype or hope?
Feng Y, Wang Y, Cao N, Yang H, Wang Y. Feng Y, et al. Ann Palliat Med. 2012;1(1):65-77. doi: 10.3978/j.issn.2224-5820.2012.04.01. Ann Palliat Med. 2012. PMID: 22833840 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical